in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
ScinoPharm to Invest in U.S. Biologics Firm
12:04 AM MDT | September 1, 2010 | Deepti Ramesh
Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm (Shan-Hua, Taiwan) says it will invest in Tanvex Biologics (Irvine, CA), which specializes in the development of biosimilars and biobetters, as well as the provision of contract research and contract manufacturing services for biologics. ScinoPharm's investment is in the form of tangible assets, intellectual properties, as well as cash, the company says. Financial details of the deal were not disclosed. Tanvex is currently establishing a cGMP facility at San Diego, CA and will have research centers...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee